<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662010"><TermName>milatuzumab</TermName><TermPronunciation>(MIH-luh-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. Milatuzumab is a type of monoclonal antibody. Also called hLL1 and IMMU-110.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725772" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;milatuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725771" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;milatuzumab&quot;" language="es" id="_4"/><SpanishTermName>milatuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia bajo estudio para el tratamiento del mieloma múltiple y varios tipos de cáncer. Se une a la proteína CD74 en la superficie de las células de mieloma y ciertos tipos de células. Podría ayudar a eliminar las células de cáncer. El milatuzumab es un tipo de anticuerpo monoclonal. También se llama hLL1 y IMMU-110.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-07</DateFirstPublished></GlossaryTerm>
